对潜在的抗风湿性关节炎候选药物的安全性评估,莱瓦米索尔
Jun-Xiang Wang1, Jia-Hui Zhang1, Mu Guo1
1School of Pharmacy & Fujian Center for New Drug Safety Evaluation, Fujian Medical University, Fuzhou, 350122, People's Republic of China.
Journal of inflammation research
|November 4, 2024
概括
在临床前研究中,Levamisole (LVM) 在治疗类风湿性关节炎 (RA) 中具有极小毒性方面表现有前途. 这种免疫调节器为RA患者提供了潜在的更安全,更有效的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 类风湿病学 类风湿病学
背景情况:
- 目前的类风湿性关节炎 (RA) 治疗有局限性和不良影响,需要新的治疗策略.
- 列瓦米索尔 (LVM) 是一种非特异性免疫调节剂,在治疗包括自身免疫性疾病在内的各种疾病方面表现出潜力.
- 尽管有争议的声誉,但LVM的免疫调节特性需要对RA治疗进行调查.
研究的目的:
- 在临床前环境中研究Levamisole (LVM) 的安全性.
- 在类风湿性关节炎 (RA) 模型中评估LVM的治疗疗效.
- 建立LVM作为潜在的更安全的RA管理替代品.
主要方法:
- 在Sprague-Dawley (SD) 老鼠中进行了为期28天的口服LVM,以评估毒性.
- 使用血清生化指标,莫里斯水迷宫测试,传输电子显微镜和H&E染色来评估一般毒性和神经毒性.
- 随后评估了LVM对RA的治疗效果.
主要成果:
- 列瓦米索尔 (LVM) 剂量为30mg/kg,在治疗类风湿性关节炎 (RA) 中显示出显著的治疗效果.
- 对于LVM,在剂量从45毫克/公斤到180毫克/公斤之间观察到微不足道的毒性.
- 这项研究确定了LVM在RA治疗中的有前途的治疗窗口.
结论:
- 列瓦米索尔 (LVM) 显示出安全性和有效性,为风湿性关节炎 (RA) 治疗提供了宝贵的临床前数据.
- 这些发现支持LVM作为RA患者更安全,更有效的治疗选择的潜力.
- 需要进一步的临床研究来将这些临床前发现转化为人类应用.
更多相关视频
11:03A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
Published on: October 30, 2019
8.2K
04:50Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
85
相关概念视频
Therapeutic Index
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
